Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenyleneiodonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 16/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | CYBB | P04839 | 2/20 | 0.70 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.70 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.70 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
| ▸ | STAT6 | P42226 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenyleneiodonium SCHEMBL3733575 | 0.91 | GPR3 (0.68) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL219548 | 0.84 | GPR3 (1.00) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL29486373 | 0.84 | GPR3 (1.00) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL10834144 | 0.81 | GPR3 (0.93) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL30150802 | 0.81 | GPR3 (1.00) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL159318 | 0.81 | GPR3 (1.00) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL5547280 | 0.78 | GPR3 (0.94) | GPR3MEN1KMT2ACYBBNOX5 | |
| Anthraquinone SCHEMBL5082838 | 0.70 | MEN1 (0.71) | MEN1KMT2ANPC1MAPK1SMN1; SMN2 | |
| SCHEMBL8367212 | 0.67 | — | — | |
| Naphthoquinone SCHEMBL8156848 | 0.65 | IDO1 (0.70) | MEN1KMT2ANPC1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350176-B2 | Pharmaceutical composition consisting of diphenyleneiodonium for treating diseases caused by the parasites belonging to the family trypanosomatidae | INSTITUTE OF MOLECULAR GENETICS, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2019-07-16 | — | — | US | disclosed |
| US-20170320964-A1 | Modulators of ACYL-COA Lysocardiolipin Acyltransferase 1 (ALCAT1) and Uses Thereof | THE PENN STATE RESEARCH FOUNDATION | 2017-11-09 | — | — | US | disclosed |
| US-9770444-B2 | Compositions and methods for modulating circadian synchronization | MAX-PLANCK-GESELLSCHAFT-ZUR-FÖRDERUNG DER WISSENSCHAFTEN E.V (DE) | 2017-09-26 | — | — | US | disclosed |
| EP-3054941-B1 | PHARMACEUTICAL COMPOSITION COMPRISING DIPHENYLENEIODONIUM FOR TREATING DISEASES CAUSED BY THE PARASITES BELONGING TO THE FAMILY TRYPANOSOMATIDAE | USTAV MOLEKULARNI GENETIKY AV CR V V I (CZ) | 2017-07-19 | — | — | EP | disclosed |
| US-9708411-B2 | Modulators of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) and uses thereof | THE PENN RESEARCH FOUNDATION (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3054941-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DIPHENYLENEIODONIUM FOR TREATING DISEASES CAUSED BY THE PARASITES BELONGING TO THE FAMILY TRYPANOSOMATIDAE | Ustav molekularni genetiky AV CR, v.v.i. (CZ) | 2016-08-17 | — | — | EP | disclosed |
| US-20160220508-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DIPHENYLENEIODONIUM FOR TREATING DISEASES CAUSED BY THE PARASITES BELONGING TO THE FAMILY TRYPANOSOMATIDAE | INSTITUTE OF MOLECULAR GENETICS, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2016-08-04 | — | — | US | disclosed |
| US-20150105428-A1 | COMPOSITIONS AND METHODS FOR MODULATING CIRCADIAN SYNCHRONIZATION | Max-Planck-Gesellschaft-zur-Förderung der Wissenschaften e.V. (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150098938-A1 | Modulators of ACYL-COA Lysocardiolipin Acyltransferase 1 (ALCAT1) and Uses Thereof | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-04-09 | — | — | US | disclosed |
| WO-2015039638-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DIPHENYLENEIODONIUM FOR TREATING DISEASES CAUSED BY THE PARASITES BELONGING TO THE FAMILY TRYPANOSOMATIDAE | Ústav molekulární genetiky AV ČR, v.v.i. (CZ) | 2015-03-26 | — | — | WO | disclosed |
| EP-2822571-A1 | MODULATORS OF ACYL-COA LYSOCARDIOLIPIN ACYLTRANSFERASE 1 ( ALCAT1) AND USES THEREOF | The Penn State Research Foundation (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8541197-B2 | Targets, including Yap1, for antifungal drug discovery and therapy | WORCESTER POLYTECHNIC INSTITUTE (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2013123305-A1 | MODULATORS OF ACYL-COA LYSOCARDIOLIPIN ACYLTRANSFERASE 1 ( ALCAT1) AND USES THEREOF | THE PENN STATE RESEARCH FOUNDATION (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20120230978-A1 | COMPOSITIONS AND METHODS FOR MODULATING CIRCADIAN SYNCHRONIZATION | Max-Planck-Gesellschaft-zur-Forderung der Wissenschaften e.V. (DE) | 2012-09-13 | — | — | US | disclosed |
| WO-2011134019-A1 | NOVEL BIPHENYL SARTANS | THE UNIVERSITY OF MELBOURNE (AU) | 2011-11-03 | — | — | WO | disclosed |
| US-20110250134-A1 | SUSTAINED RELEASE NITRIC OXIDE FROM LONG LIVED CIRCULATING NANOPARTICLES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2011-10-13 | — | — | US | disclosed |
| US-20110033442-A1 | TARGETS, INCLUDING YAP1, FOR ANTIFUNGAL DRUG DISCOVERY AND THERAPY | WORCESTER POLYTECHNIC INSTITUTE (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2118265-A1 | TARGETS, INCLUDING YAP1, FOR ANTIFUNGAL DRUG DISCOVERY AND THERAPY | Worcester Polytechnic Institute (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008073900-A1 | TARGETS, INCLUDING YAP1, FOR ANTIFUNGAL DRUG DISCOVERY AND THERAPY | WORCESTER POLYTECHNIC INSTITUTE (WPI) (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007080598-A2 | A PHARMACEUTICAL COMPOSITION FOR INHIBITING/REDUCING NEOINTIMAL PROLIFERATION AND RESTENOSIS. | CHANDRASEKAR BASKARAN (IN) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350176-B2 | Pharmaceutical composition consisting of diphenyleneiodonium for treating diseases caused by the parasites belonging to the family trypanosomatidae | MT-ND5, QDPR, MT-ND1 | GPR3 2882/4885MEN1 3037/4885KMT2A 3611/4885 |
| US-20160220508-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DIPHENYLENEIODONIUM FOR TREATING DISEASES CAUSED BY THE PARASITES BELONGING TO THE FAMILY TRYPANOSOMATIDAE | MT-ND5, QDPR, MT-ND1 | GPR3 2596/4885MEN1 3292/4885KMT2A 3597/4885 |
| US-20120230978-A1 | COMPOSITIONS AND METHODS FOR MODULATING CIRCADIAN SYNCHRONIZATION | PER2, CRY1, NR3C1 | GPR3 175/4885MEN1 1146/4885KMT2A 2432/4885 |
| US-20150105428-A1 | COMPOSITIONS AND METHODS FOR MODULATING CIRCADIAN SYNCHRONIZATION | PER2, CRY1, NR3C1 | GPR3 175/4885MEN1 1146/4885KMT2A 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.